Published in Biochem Biophys Res Commun on March 18, 2005
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone (2007) 3.41
Molecular recognition of parathyroid hormone by its G protein-coupled receptor. Proc Natl Acad Sci U S A (2008) 2.27
Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev (2008) 2.22
PTH and PTHrP signaling in osteoblasts. Cell Signal (2009) 1.69
Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism. Proc Natl Acad Sci U S A (2005) 1.63
Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol Endocrinol (2007) 1.57
Regulation of bone formation and remodeling by G-protein-coupled receptor 48. Development (2009) 1.50
Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation. Proc Natl Acad Sci U S A (2008) 1.45
Wnt/beta-catenin signaling and small molecule inhibitors. Curr Pharm Des (2013) 1.44
Mechanisms of ligand binding to the parathyroid hormone (PTH)/PTH-related protein receptor: selectivity of a modified PTH(1-15) radioligand for GalphaS-coupled receptor conformations. Mol Endocrinol (2005) 1.36
Regulation of phosphate transport in proximal tubules. Pflugers Arch (2008) 1.33
T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab (2009) 1.32
Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm. Cell Mol Life Sci (2010) 1.30
NHERF1 regulates parathyroid hormone receptor desensitization: interference with beta-arrestin binding. Mol Pharmacol (2009) 1.20
Conditional expression of a Gi-coupled receptor in osteoblasts results in trabecular osteopenia. Endocrinology (2007) 1.20
PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. J Clin Invest (2011) 1.17
PTH-induced internalization of apical membrane NaPi2a: role of actin and myosin VI. Am J Physiol Cell Physiol (2009) 1.14
Parathyroid hormone-related protein: an update. J Clin Endocrinol Metab (2012) 1.13
Postnatal establishment of allelic Gαs silencing as a plausible explanation for delayed onset of parathyroid hormone resistance owing to heterozygous Gαs disruption. J Bone Miner Res (2014) 1.10
Calcium and bone disease. Biofactors (2011) 1.02
Treatment for chemotherapy-induced alopecia in mice using parathyroid hormone agonists and antagonists linked to a collagen binding domain. Int J Cancer (2012) 1.02
The TIP39-PTH2 receptor system: unique peptidergic cell groups in the brainstem and their interactions with central regulatory mechanisms. Prog Neurobiol (2009) 0.99
The GNAS Locus: Quintessential Complex Gene Encoding Gsalpha, XLalphas, and other Imprinted Transcripts. Curr Genomics (2007) 0.97
Non-canonical signaling of the PTH receptor. Trends Pharmacol Sci (2012) 0.95
Parathyroid hormone suppresses osteoblast apoptosis by augmenting DNA repair. Bone (2009) 0.94
Accentuated osteoclastic response to parathyroid hormone undermines bone mass acquisition in osteonectin-null mice. Bone (2008) 0.93
Functional characterization and evolution of PTH/PTHrP receptors: insights from the chicken. BMC Evol Biol (2012) 0.92
Residue 17 of sauvagine cross-links to the first transmembrane domain of corticotropin-releasing factor receptor 1 (CRFR1). J Biol Chem (2008) 0.85
TIP39/parathyroid hormone type 2 receptor signaling is a potent inhibitor of chondrocyte proliferation and differentiation. Am J Physiol Endocrinol Metab (2009) 0.85
Enhancement of taxol, doxorubicin and zoledronate anti-proliferation action on triple-negative breast cancer cells by a PTHrP blocking monoclonal antibody. Am J Cancer Res (2013) 0.85
PTH and PTH antagonist induce different conformational changes in the PTHR1 receptor. J Bone Miner Res (2009) 0.84
International Union of Basic and Clinical Pharmacology. XCIII. The parathyroid hormone receptors--family B G protein-coupled receptors. Pharmacol Rev (2015) 0.83
Biophysical characterization of G-protein coupled receptor-peptide ligand binding. Biochem Cell Biol (2011) 0.83
A novel population of cells expressing both hematopoietic and mesenchymal markers is present in the normal adult bone marrow and is augmented in a murine model of marrow fibrosis. Am J Pathol (2011) 0.82
Constitutive protein kinase A activity in osteocytes and late osteoblasts produces an anabolic effect on bone. Bone (2013) 0.82
Tuberoinfundibular peptide of 39 residues in the embryonic and early postnatal rat brain. J Chem Neuroanat (2008) 0.82
Cyclic AMP signaling in bone marrow stromal cells has reciprocal effects on the ability of mesenchymal stem cells to differentiate into mature osteoblasts versus mature adipocytes. Endocrine (2012) 0.82
Gene structure, transcripts and calciotropic effects of the PTH family of peptides in Xenopus and chicken. BMC Evol Biol (2010) 0.82
Eliminating phosphorylation sites of the parathyroid hormone receptor type 1 differentially affects stimulation of phospholipase C and receptor internalization. Am J Physiol Endocrinol Metab (2008) 0.81
Actions of the small molecule ligands SW106 and AH-3960 on the type-1 parathyroid hormone receptor. Mol Endocrinol (2015) 0.80
Conformational changes in the parathyroid hormone receptor associated with activation by agonist. Mol Endocrinol (2008) 0.80
PTHrP is a novel mediator for TGF-β-induced apoptosis. Regul Pept (2013) 0.80
Acrodysostosis syndromes. Bonekey Rep (2012) 0.80
Recombinant expression and purification of the N-terminal extracellular domain of the parathyroid hormone receptor. Protein Expr Purif (2007) 0.79
Nematode and arthropod genomes provide new insights into the evolution of class 2 B1 GPCRs. PLoS One (2014) 0.78
Folding and function in α/β-peptides: targets and therapeutic applications. Curr Opin Chem Biol (2015) 0.78
Parathyroid hormone and its receptor gene polymorphisms: implications in osteoporosis and in fracture healing. Rheumatol Int (2015) 0.77
PTHrP expression in human MDA-MB-231 breast cancer cells is critical for tumor growth and survival and osteoblast inhibition. Int J Biol Sci (2013) 0.77
Role of regulator of G protein signaling proteins in bone. Front Biosci (Landmark Ed) (2014) 0.77
Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. Oncologist (2012) 0.77
Agonist-regulated cleavage of the extracellular domain of parathyroid hormone receptor type 1. J Biol Chem (2010) 0.77
Deletion of the nuclear localization sequences and C-terminus of PTHrP impairs embryonic mammary development but also inhibits PTHrP production. PLoS One (2014) 0.77
JunB as a potential mediator of PTHrP actions: new gene targets Ephrin B1 and VCAM-1. Oral Dis (2008) 0.77
Prediagnostic circulating parathyroid hormone concentration and colorectal cancer in the European Prospective Investigation into Cancer and Nutrition cohort. Cancer Epidemiol Biomarkers Prev (2011) 0.77
Pseudohypoparathyroidism and Gsα-cAMP-linked disorders: current view and open issues. Nat Rev Endocrinol (2016) 0.76
Crystallization of the receptor-binding domain of parathyroid hormone-related protein in complex with a neutralizing monoclonal antibody Fab fragment. Acta Crystallogr Sect F Struct Biol Cryst Commun (2009) 0.76
Adrenal effects of teriparatide in the treatment of severe postmenopausal osteoporosis. Osteoporos Int (2010) 0.76
Small Molecule Inhibited Parathyroid Hormone Mediated cAMP Response by N-Terminal Peptide Binding. Sci Rep (2016) 0.76
PTH1R Mutants Found in Patients with Primary Failure of Tooth Eruption Disrupt G-Protein Signaling. PLoS One (2016) 0.75
Robust Circadian Rhythm and Parathyroid Hormone-Induced Resetting during Hypertrophic Differentiation in ATDC5 Chondroprogenitor Cells. Acta Histochem Cytochem (2015) 0.75
Effects of phospho- and calciotropic hormones on electrolyte transport in the proximal tubule. F1000Res (2017) 0.75
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med (2003) 8.87
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol (2005) 5.76
DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet (2006) 4.49
Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology (2004) 3.89
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int (2003) 3.75
Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res (2006) 3.66
Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol (2004) 3.23
Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat Chem Biol (2009) 3.03
Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. Annu Rev Med (2010) 2.55
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int (2010) 2.31
Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res (2011) 2.30
Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant (2010) 2.23
A mutant PTH/PTHrP type I receptor in enchondromatosis. Nat Genet (2002) 2.19
Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab (2009) 2.12
Ollier disease. Orphanet J Rare Dis (2006) 2.11
Retromer terminates the generation of cAMP by internalized PTH receptors. Nat Chem Biol (2011) 1.88
A novel missense mutation in SLC34A3 that causes hereditary hypophosphatemic rickets with hypercalciuria in humans identifies threonine 137 as an important determinant of sodium-phosphate cotransport in NaPi-IIc. Am J Physiol Renal Physiol (2008) 1.81
Autosomal dominant pseudohypoparathyroidism type Ib is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. J Clin Invest (2003) 1.77
First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int (2005) 1.74
Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH. Proc Natl Acad Sci U S A (2013) 1.68
Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type Ib. Nat Genet (2004) 1.68
A novel COL1A1 mutation in infantile cortical hyperostosis (Caffey disease) expands the spectrum of collagen-related disorders. J Clin Invest (2005) 1.68
Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab (2008) 1.67
Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23? Nephrol Dial Transplant (2011) 1.57
Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol Endocrinol (2007) 1.57
Dosage-dependent switch from G protein-coupled to G protein-independent signaling by a GPCR. EMBO J (2006) 1.56
GNAS locus and pseudohypoparathyroidism. Horm Res (2005) 1.56
Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo. Proc Natl Acad Sci U S A (2004) 1.46
Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation. Proc Natl Acad Sci U S A (2008) 1.45
A novel STX16 deletion in autosomal dominant pseudohypoparathyroidism type Ib redefines the boundaries of a cis-acting imprinting control element of GNAS. Am J Hum Genet (2005) 1.43
Germline mutations affecting Gα11 in hypoparathyroidism. N Engl J Med (2013) 1.43
Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int (2013) 1.42
Epigenetic defects of GNAS in patients with pseudohypoparathyroidism and mild features of Albright's hereditary osteodystrophy. J Clin Endocrinol Metab (2007) 1.41
Receptor-mediated adenylyl cyclase activation through XLalpha(s), the extra-large variant of the stimulatory G protein alpha-subunit. Mol Endocrinol (2002) 1.40
Structural basis for parathyroid hormone-related protein binding to the parathyroid hormone receptor and design of conformation-selective peptides. J Biol Chem (2009) 1.36
Mechanisms of ligand binding to the parathyroid hormone (PTH)/PTH-related protein receptor: selectivity of a modified PTH(1-15) radioligand for GalphaS-coupled receptor conformations. Mol Endocrinol (2005) 1.36
Progress, paradox, and potential: parathyroid hormone research over five decades. Ann N Y Acad Sci (2007) 1.31
Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm. Cell Mol Life Sci (2010) 1.30
Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis. J Clin Endocrinol Metab (2009) 1.28
Deletion of the noncoding GNAS antisense transcript causes pseudohypoparathyroidism type Ib and biparental defects of GNAS methylation in cis. J Clin Endocrinol Metab (2010) 1.28
Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.25
Clinical case seminar: Fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab (2003) 1.22
PHEX, FGF23, DMP1 and beyond. Curr Opin Nephrol Hypertens (2008) 1.22
Multicystic dysplastic kidney and variable phenotype in a family with a novel deletion mutation of PAX2. J Am Soc Nephrol (2005) 1.16
Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype. J Bone Miner Res (2005) 1.12
Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia. J Clin Endocrinol Metab (2008) 1.11
The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84). J Clin Endocrinol Metab (2010) 1.08
Similar clinical and laboratory findings in patients with symptomatic autosomal dominant and sporadic pseudohypoparathyroidism type Ib despite different epigenetic changes at the GNAS locus. Clin Endocrinol (Oxf) (2007) 1.07
Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol (2013) 1.05
Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma. J Clin Endocrinol Metab (2013) 1.05
Identification of a contact site for residue 19 of parathyroid hormone (PTH) and PTH-related protein analogs in transmembrane domain two of the type 1 PTH receptor. Mol Endocrinol (2003) 1.04
Paternal uniparental isodisomy of the entire chromosome 20 as a molecular cause of pseudohypoparathyroidism type Ib (PHP-Ib). Bone (2010) 1.04
Phenotypic and molecular genetic aspects of pseudohypoparathyroidism type Ib in a Greek kindred: evidence for enhanced uric acid excretion due to parathyroid hormone resistance. J Clin Endocrinol Metab (2004) 1.03
Editorial: Pseudohypoparathyroidism and mechanisms of resistance toward multiple hormones: molecular evidence to clinical presentation. J Clin Endocrinol Metab (2003) 1.03
Endosomal generation of cAMP in GPCR signaling. Nat Chem Biol (2014) 1.03
Targeted deletion of the Nesp55 DMR defines another Gnas imprinting control region and provides a mouse model of autosomal dominant PHP-Ib. Proc Natl Acad Sci U S A (2010) 1.02
Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol. Clin J Am Soc Nephrol (2012) 1.02
Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity. BMC Med Genet (2012) 1.00
Coding GNAS mutations leading to hormone resistance impair in vitro agonist- and cholera toxin-induced adenosine cyclic 3',5'-monophosphate formation mediated by human XLalphas. Endocrinology (2006) 1.00
Dominant-negative GCMB mutations cause an autosomal dominant form of hypoparathyroidism. J Clin Endocrinol Metab (2008) 1.00
Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol (2005) 1.00
Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab (2009) 0.99
Paternal GNAS mutations lead to severe intrauterine growth retardation (IUGR) and provide evidence for a role of XLαs in fetal development. J Clin Endocrinol Metab (2013) 0.99
Novel parathyroid hormone (PTH) antagonists that bind to the juxtamembrane portion of the PTH/PTH-related protein receptor. J Biol Chem (2004) 0.99
Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int (2003) 0.98
Inherited hypophosphatemic disorders in children and the evolving mechanisms of phosphate regulation. Rev Endocr Metab Disord (2008) 0.97
Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Hum Mol Genet (2013) 0.96
Non-canonical signaling of the PTH receptor. Trends Pharmacol Sci (2012) 0.95
Acute down-regulation of sodium-dependent phosphate transporter NPT2a involves predominantly the cAMP/PKA pathway as revealed by signaling-selective parathyroid hormone analogs. J Biol Chem (2010) 0.95
Identification of a novel dentin matrix protein-1 (DMP-1) mutation and dental anomalies in a kindred with autosomal recessive hypophosphatemia. Bone (2009) 0.95
Identification and characterization of two parathyroid hormone-like molecules in zebrafish. Endocrinology (2003) 0.95
Identification and characterization of the murine and human gene encoding the tuberoinfundibular peptide of 39 residues. Endocrinology (2002) 0.94
A form of Jansen's metaphyseal chondrodysplasia with limited metabolic and skeletal abnormalities is caused by a novel activating parathyroid hormone (PTH)/PTH-related peptide receptor mutation. J Clin Endocrinol Metab (2004) 0.94
Phosphate sensing. Adv Chronic Kidney Dis (2011) 0.93
Role of amino acid side chains in region 17-31 of parathyroid hormone (PTH) in binding to the PTH receptor. J Biol Chem (2006) 0.93
Parathyroid hormone signaling via Gαs is selectively inhibited by an NH(2)-terminally truncated Gαs: implications for pseudohypoparathyroidism. J Bone Miner Res (2011) 0.92
Exclusion of the GNAS locus in PHP-Ib patients with broad GNAS methylation changes: evidence for an autosomal recessive form of PHP-Ib? J Bone Miner Res (2011) 0.92
FGF23 and syndromes of abnormal renal phosphate handling. Adv Exp Med Biol (2012) 0.92
New lessons from old assays: parathyroid hormone (PTH), its receptors, and the potential biological relevance of PTH fragments. Nephrol Dial Transplant (2002) 0.91
The role of fibroblast growth factor 23 for hypophosphatemia and abnormal regulation of vitamin D metabolism in patients with McCune-Albright syndrome. J Bone Miner Metab (2005) 0.91
Amino-terminal parathyroid hormone fragment analogs containing alpha,alpha-di-alkyl amino acids at positions 1 and 3. J Bone Miner Res (2004) 0.90
Long-term clinical outcome and carrier phenotype in autosomal recessive hypophosphatemia caused by a novel DMP1 mutation. J Bone Miner Res (2010) 0.90
Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy. Kidney Int (2003) 0.89
Immunohistochemical detection of FGF-23 protein in tumors that cause oncogenic osteomalacia. Eur J Endocrinol (2003) 0.89
Regulation of calcium homeostasis and bone metabolism in the fetus and neonate. Curr Opin Endocrinol Diabetes Obes (2010) 0.89
Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols. Pediatr Nephrol (2009) 0.89
Osteosclerosis in two brothers with autosomal dominant pseudohypoparathyroidism type 1b: bone histomorphometric analysis. Eur J Endocrinol (2010) 0.88
De novo STX16 deletions: an infrequent cause of pseudohypoparathyroidism type Ib that should be excluded in sporadic cases. J Clin Endocrinol Metab (2012) 0.88
Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation. Am J Kidney Dis (2013) 0.88
Disorders of phosphate homeostasis and tissue mineralisation. Endocr Dev (2009) 0.88
Activation of a non-cAMP/PKA signaling pathway downstream of the PTH/PTHrP receptor is essential for a sustained hypophosphatemic response to PTH infusion in male mice. Endocrinology (2013) 0.87
Loss of XLαs (extra-large αs) imprinting results in early postnatal hypoglycemia and lethality in a mouse model of pseudohypoparathyroidism Ib. Proc Natl Acad Sci U S A (2012) 0.87
Heterotopic ossifications in a mouse model of albright hereditary osteodystrophy. PLoS One (2011) 0.87
TIP39/parathyroid hormone type 2 receptor signaling is a potent inhibitor of chondrocyte proliferation and differentiation. Am J Physiol Endocrinol Metab (2009) 0.85
Molecular diagnosis of pseudohypoparathyroidism type Ib in a family with presumed paroxysmal dyskinesia. Pediatrics (2005) 0.84